Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown 228 enrolled Samsung Medical Center

RandomizedParallel-groupOpen-labelTreatment

Summary

This randomized, Phase III, multicenter, open-label study designed to evaluate the efficacy of Atezolizumab in combination with carboplatin, paclitaxel, bevacizumab compared with treatment with pemetrexed, cisplatin in approximately 228 TKI(tyrosine kinase inhibitor) pre treated patients with Stage IV non squamous non small cell lung cancer with activating EGFR mutation or ALK translocation.

Timeline

Start: 2019-08-27
Primary completion: 2023-03-11
Completion: 2024-03-11

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	1200 mg	Intravenous
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Carboplatin	Small molecule	5.5 unknown	Intravenous
Comparator	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	175 mg/m2	Intravenous
Comparator	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Summary

Timeline

Publications

Drugs

Indications